Butyrogenic bacteria as probiotics to treat clostridium difficile
View Patent ↗The subject invention pertains to the use of certain bacterial strains, particularly butyrogenic bacteria, for preparing a composition to treat and/or prevent Clostridium difficile infection. In particular, the invention relates to the use of butyrate-producing anaerobic fermenters of gut commensals in pharmaceutical or food compositions.
1. A method for treating Clostridium difficile infection (CDI) comprising the step of administering to a mammal an effective amount of a composition comprising at least one strain of bacteria from the genus Pseudobutryrivibrio and, optionally, at least one other strain from the following butyrogenic bacterial genera: Blautia, Roseburia, Dorea , and Coprococcus.
2. The method of claim 1 , wherein the composition comprises more than one strain of bacteria.
3. The method of claim 1 , wherein the composition further comprises at least one strain from the following additional bacterial taxa: Faecalibacterium, Anaerostipes, Subdoligranulum, Ruminoccocus, Streptococcus , and Lachnospiraceae.
4. The method of claim 3 , wherein the composition further comprises more than one additional strain of bacteria.
5. The method of claim 1 , further comprising the step of diagnosing the CDI in the mammal.
6. The method of claim 1 , further comprising the step of monitoring the CDI in the mammal.